Tag: Biotech industry
Ending 23andMe’s Drug Discovery Dream: What Went Wrong?
23andMe, the genetics company that many people have been excited about, recently made a big announcement. The company has decided to stop working on creating new medicines and will be letting go of 40%...
David Epstein launches new cancer startup after Novartis and Seagen career
David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop a drug that targets two proteins, PD-1 and VEGF, in...
BREAKING NEWS
Reforming FDA Advisory Committee Policy for Conflict of Interest-Free Decisions
Peter J. Pitts, a distinguished figure in the realm of healthcare regulation, recently shared his insights on the critical issue of FDA Advisory Committee...
